173 related articles for article (PubMed ID: 35234143)
1. High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system.
Heim C; Hartmann MD
Acta Crystallogr D Struct Biol; 2022 Mar; 78(Pt 3):290-298. PubMed ID: 35234143
[TBL] [Abstract][Full Text] [Related]
2. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
3. [Cereblon as a primary target of IMiDs].
Ito T; Handa H
Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
[TBL] [Abstract][Full Text] [Related]
4. CRL4
Barankiewicz J; Salomon-Perzyński A; Misiewicz-Krzemińska I; Lech-Marańda E
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139651
[TBL] [Abstract][Full Text] [Related]
5. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
[TBL] [Abstract][Full Text] [Related]
6. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
7. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.
Costacurta M; He J; Thompson PE; Shortt J
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834536
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of thalidomide and its derivatives.
Ito T; Handa H
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
[TBL] [Abstract][Full Text] [Related]
10. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
11. [Recent topics in IMiDs and cereblon].
Ito T; Handa H
Rinsho Ketsueki; 2017; 58(10):2067-2073. PubMed ID: 28978850
[TBL] [Abstract][Full Text] [Related]
12. Ligands for cereblon: 2017-2021 patent overview.
Kazantsev A; Krasavin M
Expert Opin Ther Pat; 2022 Feb; 32(2):171-190. PubMed ID: 34704527
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
14. First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
Ye Y; Gaudy A; Schafer P; Thomas M; Weiss D; Chen N; Liu L; Xue Y; Carayannopoulos L; Palmisano M
Clin Pharmacol Drug Dev; 2021 May; 10(5):471-485. PubMed ID: 32969202
[TBL] [Abstract][Full Text] [Related]
15. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Schafer PH; Ye Y; Wu L; Kosek J; Ringheim G; Yang Z; Liu L; Thomas M; Palmisano M; Chopra R
Ann Rheum Dis; 2018 Oct; 77(10):1516-1523. PubMed ID: 29945920
[TBL] [Abstract][Full Text] [Related]
16. Novel immunomodulatory drugs and neo-substrates.
Gao S; Wang S; Song Y
Biomark Res; 2020; 8():2. PubMed ID: 31938543
[TBL] [Abstract][Full Text] [Related]
17. Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron.
Heim C; Spring AK; Kirchgäßner S; Schwarzer D; Hartmann MD
Biochem Biophys Res Commun; 2023 Feb; 646():30-35. PubMed ID: 36701892
[TBL] [Abstract][Full Text] [Related]
18. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Surka C; Jin L; Mbong N; Lu CC; Jang IS; Rychak E; Mendy D; Clayton T; Tindall E; Hsu C; Fontanillo C; Tran E; Contreras A; Ng SWK; Matyskiela M; Wang K; Chamberlain P; Cathers B; Carmichael J; Hansen J; Wang JCY; Minden MD; Fan J; Pierce DW; Pourdehnad M; Rolfe M; Lopez-Girona A; Dick JE; Lu G
Blood; 2021 Feb; 137(5):661-677. PubMed ID: 33197925
[TBL] [Abstract][Full Text] [Related]
19. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
Zhou L; Xu G
J Mol Biol; 2022 Mar; 434(5):167457. PubMed ID: 35045330
[TBL] [Abstract][Full Text] [Related]
20. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH
Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
